Position in RGNX
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$799,452
+$799,452 QoQ
Shares Held
95,400
Ownership
0.185%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2023
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in RGNX Over Time
Shares Held
Position Value (USD)
Derivatives in RGNX
reported options exposure · as of Sep 30, 2024CallValue
$0
CallShares
0
PutValue
$4,196,000
PutShares
400,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Jefferies Financial Group Inc. holds $507,365,833 across 84 Biotechnology names. RGNX ranks #50 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PTCT |
Ptc Therapeutics, Inc.
|
1,354,459 | $92,279,291 | |
| 2 | IMTX |
Immatics N.V.
|
5,059,551 | $49,785,981 | |
| 3 | URGN |
UroGen Pharma Ltd.
|
2,199,652 | $39,549,742 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
175,599 | $33,196,990 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
468,146 | $26,445,567 | |
| 6 | IMNM |
Immunome Inc.
|
1,160,715 | $25,384,837 | |
| 7 | ARGX |
Argenx SE
|
30,005 | $21,911,151 | |
| 8 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
202,410 | $16,986,247 |
All Filings in RGNX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $799,452 | 95,400 | Shares | Defined | 2026-05-08 | |
| 2024-09-30 | $4,196,000 | 400,000 | Put | Defined | 2024-11-14 | |
| 2023-03-31 | $1,272,851 | 67,311 | Shares | Defined | 2023-05-15 | |
| No filing history on record for this holder in this stock. | ||||||